What is the fair value of Ocugen, Inc (NASDAQ-OCGN) stock?

The current fair value estimate for Ocugen, Inc (NASDAQ-OCGN) is $1.36. This implies an estimated upside of 3.4% versus the current market price.

Is Ocugen, Inc (NASDAQ-OCGN) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 3.4% versus the current market price.

What is the analyst price target for NASDAQ-OCGN stock?

The available analyst price target for Ocugen, Inc (NASDAQ-OCGN) is $11.43. The analyst target implies estimated upside of 769.1%.

How is the financial health of Ocugen, Inc?

The current financial health read for Ocugen, Inc (NASDAQ-OCGN) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Ocugen, Inc's next earnings date?

The next earnings date currently listed for Ocugen, Inc (NASDAQ-OCGN) is July 31, 2026.

Does Ocugen, Inc (NASDAQ-OCGN) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for Ocugen, Inc (NASDAQ-OCGN)?

The current P/E ratio listed for Ocugen, Inc (NASDAQ-OCGN) is -6.3x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Ocugen, Inc?

The current market capitalization listed for Ocugen, Inc is 450.2 M.

What is the enterprise value of Ocugen, Inc?

The current enterprise value listed for Ocugen, Inc is 450 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Ocugen, Inc?

The ticker symbol for Ocugen, Inc is NASDAQ-OCGN, and the stock is listed on NASDAQ.

Where is Ocugen, Inc (NASDAQ-OCGN) listed?

Ocugen, Inc (NASDAQ-OCGN) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Ocugen, Inc?

The current debt-to-total-capital ratio listed for Ocugen, Inc is 6.9%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Ocugen, Inc?

The free float listed for Ocugen, Inc is 93.6%. Free float helps investors understand how much of the share base is available for public trading.

Ocugen, Inc (OCGN) Fair Value & Stock Analysis

Ocugen, Inc (OCGN)

Ocugen, Inc. is a NASDAQ-listed biopharmaceutical company focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines. Its pipeline includes OCU400, a gene therapy candidate being studied in Phase 3 for retinitis pigmentosa and in Phase 1/2 for leber congenital amaurosis; OCU410 and OCU410ST, both in Phase 1/2 for dry age-related macular degeneration and Stargardt disease, respectively; and OCU200, a recombinant fusion protein under development for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration. The company is also advancing NeoCart for knee cartilage repair and vaccine programs such as OCU500, OCU510, and OCU520. Ocugen was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
NASDAQ-OCGN	$1.36	3.4% Upside	Fair	$11.43	769.1% Upside	Bargain	Weak	—	—	—	0.0%	July 31, 2026	-6.3x	77.3x	100.5x	450.2 M	450 M	6.9%	93.6%	-8.6	—	83.1%